Reduction in HPV 16/18-associated high grade cervical lesions following HPV vaccine introduction in the United States - 2008-2012

Vaccine

Volumn 33, Issue 13, 2015, Pages 1608-1613

  Hariri, Susan ^a   Bennett, Nancy M ^b   Niccolai, Linda M ^c   Schafer, Sean ^d   Park, Ina U ^e   Bloch, Karen C ^f   Unger, Elizabeth R ^g   Whitney, Erin ^e   Julian, Pamela ^c   Scahill, Mary W ^b   Abdullah, Nasreen ^d   Levine, Diane ^f   Johnson, Michelle L ^a   Steinau, Martin ^g   Markowitz, Lauri E ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c YALE UNIVERSITY   (United States)

^d OREGON PUBLIC HEALTH DIVISION   (United States)

^e CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^f VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^g NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Cervical intraepithelial neoplasia; CIN; High grade cervical lesion; HPV; Human papillomavirus; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADENOCARCINOMA IN SITU; ADULT; ARTICLE; CANCER GRADING; CANCER SCREENING; CATCHMENT; DNA FINGERPRINTING; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LABORATORY; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; SENTINEL SURVEILLANCE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX DISEASE; VACCINATION; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONNECTICUT; EARLY CANCER DIAGNOSIS; ISOLATION AND PURIFICATION; NEW YORK; OREGON; TENNESSEE; TIME FACTOR; UTERINE CERVICAL DISEASES; VIROLOGY; YOUNG ADULT;

ADENOCARCINOMA IN SITU; ADULT; CALIFORNIA; CERVICAL INTRAEPITHELIAL NEOPLASIA; CONNECTICUT; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; NEW YORK; OREGON; PAPILLOMAVIRUS VACCINES; PREVALENCE; SENTINEL SURVEILLANCE; TENNESSEE; TIME FACTORS; UNITED STATES; UTERINE CERVICAL DISEASES; VACCINATION; YOUNG ADULT;

EID: 84924860226     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.084     Document Type: Article

References (24)

1. Munoz N., Castellsague X., de Gonzalez A.B., Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006, 24(Suppl. 3). S3/1-10.
2. Franco E.L., Olsen J., Saracci R., Detels R. Epidemiology's contributions to a Nobel Prize recognition. Epidemiology 2009, 20:632-634.
3. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
4. Serrano B., Alemany L., Tous S., Bruni L., Clifford G.M., Weiss T., et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agents Cancer 2012, 7:38.
5. FUTURE I/II Study Group, Dillner J., Kjaer S.K., Wheeler C.M., Sigurdsson K., Iversen O.E., et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010, 341:c3493.
6. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
7. Hariri S., Markowitz L.E., Dunne E.F., Unger E.R. Population impact of HPV vaccines: summary of early evidence. J Adolesc Health 2013, 53:679-682.
8. Baldur-Felskov B., Dehlendorff C., Munk C., Kjaer S.K. Early impact of human papillomavirus vaccination on cervical neoplasia - nationwide follow-up of young Danish women. J Natl Cancer Inst 2014, 106:djt460.
9. Gertig D.M., Brotherton J.M., Budd A.C., Drennan K., Chappell G., Saville A.M. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013, 11:227.
10. Pollock K.G., Kavanagh K., Potts A., Love J., Cuschieri K., Cubie H., et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014, 111:1824-1830.
11. Crowe E., Pandeya N., Brotherton J.M., Dobson A.J., Kisely S., Lambert S.B., et al. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014, 348:g1458.
12. Baldur-Felskov B., Dehlendorff C., Junge J., Munk C., Kjaer S.K. Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program. Cancer Causes Control 2014, 25:915-922.
13. Centers for Disease Control and Prevention FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR 2010, 59:626-629.
14. Stokley S., Jeyarajah J., Yankey D., Cano M., Gee J., Roark J., et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014 - United States. MMWR 2014, 63:620-624.
15. Elam-Evans L.D., Yankey D., Jeyarajah J., Singleton J.A., Curtis R.C., MacNeil J., et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2013. MMWR 2014, 63:625-633.
16. Centers for Disease Control and Prevention Noninfluenza vaccination coverage among adults - United States, 2011. MMWR 2013, 62:66-72.
17. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208:385-393.
18. Centers for Disease Control and Prevention Cervical cancer screening among women aged 18-30 years - United States, 2000-2010. MMWR 2013, 61:1038-1042.
19. Schiffman M., Castle P.E., Jeronimo J., Rodriguez A.C., Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907.
20. Hariri S., Unger E.R., Powell S.E., Bauer H.M., Bennett N.M., Bloch K.C., et al. The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions. Cancer Causes Control 2012, 23:281-288.
21. Broome C.V., Facklam R.R., Fraser D.W. Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 1980, 303:549-552.
22. Flagg E.W., Schwartz R., Weinstock H. Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination. Am J Public Health 2013, 103:1428-1435.
23. Powell S.E., Hariri S., Steinau M., Bauer H.M., Bennett N.M., Bloch K.C., et al. Impact of human papillomavirus (HPV) vaccination on HPV 16/18-related prevalence in precancerous cervical lesions. Vaccine 2012, 31:109-113.
24. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.